Revolution Medicines
RVMD
307 hedge funds and large institutions have $7.02B invested in Revolution Medicines in 2025 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 114 increasing their positions, 91 reducing their positions, and 33 closing their positions.
73% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 33
27% more call options, than puts
Call options by funds: $36.8M | Put options by funds: $29M
25% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 91
8% more funds holding
Funds holding: 284 → 307 (+23)
3% more capital invested
Capital invested by funds: $6.83B → $7.02B (+$191M)
1.13% less ownership
Funds ownership: 103.52% → 102.4% (-1.1%)
14% less funds holding in top 10
Funds holding in top 10: 21 → 18 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$116M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$54.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$51.7M |
| 4 |
Millennium Management
New York
|
+$47M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$46.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$232M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$58.7M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$44.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$41.7M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$37.3M |
RVMD Hedge Fund Activity: Q2 2025 in Review
307 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q2 2025, worth a combined $7.02B — up 2.8% from $6.83B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new RVMD positions and 33 closed out — a net gain of 24 holders — while 114 added to existing stakes and 91 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $116M. The largest seller was BlackRock, cutting an estimated $232M.
- 307 institutional investors held Revolution Medicines (RVMD) as of Q2 2025, up from 284 in Q1 2025.
- Funds reported $7.02B of Revolution Medicines stock for Q2 2025, up 2.8% quarter-over-quarter.
- 57 funds opened new Revolution Medicines positions in Q2 2025 and 33 closed out, a net change of +24 holders.
- The largest Revolution Medicines buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $116M added.
- The largest Revolution Medicines seller in Q2 2025 was BlackRock, an estimated $232M sold.
Based on aggregated 13F filings for Q2 2025.